Oslo University Hospital is a highly specialized hospital in charge of extensive regional and local hospital assignments. As Scandinavia’s largest hospital, we carry out more than 1.2 million patient treatments each year. The hospital has a nationwide responsibility for a number of national and multi-regional assignments, and has several national centers of competence. Oslo University Hospital is responsible for approximately 50 percent of all medical and health care research conducted at Norwegian hospitals, and is a significant role player within the education of a large variety of health care personnel.
A deputy group leader/research scientist position is available for 3 years from January 1st 2019, in the project group of Dr. Jon Amund Kyte at Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital (OUS), Radiumhospitalet. OUS is Norway’s largest hospital and medical research institution, and is accredited as Comprehensive Cancer Center by the Organisation of European Cancer Institutes. OUS Radiumhospitalet is a dedicated cancer center with a particularly strong research profile in cancer immunotherapy.
The Kyte project group aims to develop improved cancer treatment based on two strategies for immunotherapy: 1) Development of tumor-targeting chimeric antigen receptors (CARs) for T cell therapy. 2) Development of optimized regimes for combining immunological checkpoint inhibitors with established cancer treatment (immunogenic chemotherapy, radiotherapy). We aim at bringing CAR T cell therapy to solid cancers. To achieve this, we target unexplored tumor antigens and develop novel concepts for enabling CAR T cells to counter tumor tolerance. In the CAR projects, we make use of both permanently reprogrammed T –cells and transient retargeting with mRNA-based, biodegradable receptors. We have started three clinical trials in 2017/2018, ALICE (NCT03164993), ICON (NCT03409198) and REPORT (NCT03317327). These trials pioneer the strategy of combining chemo/radio-therapy known to induce immunological cell death with immune checkpoint blockade. We collect biopsies, PBMCs, feces and other samples from the trial patients. Moreover, we have access to large biobanks from other studies, with reliable clinical follow-up. Based on this material, we conduct translational studies aimed at identifying biomarkers and exploring mechanisms of response and resistance to treatment.
The project group leader, Dr. Jon Amund Kyte, is Head of the Department for Experimental Cancer Treatment, which includes the Clinical Trial Unit and has 63 employees. Kyte has combined expertise as senior clinical oncologist and immunotherapy researcher. The Kyte project group is located at the Dept. of Cancer Immunology and includes four postdocs, two technicians and two PhD-students.
The application must include:
- The application letter (including a summary of applicant’s scientific work and interest and describing how she/he fits the description of the person we seek)
- CV (summarizing education, positions and other qualifying activity)
- Copies of educational certificates with grades, letters of recommendation
Names, email and telephone number of 3 referees (describe relation to applicant)
- A complete list of publications
The application with attachments must be delivered in our electronic recruiting system, please follow the link “apply for position”.
The chosen candidate will work as research scientist in the Kyte project group at the Dept. of Cancer Immunology and assume a role as deputy group leader. The position will allow for active research combined with the development of a scientific profile and leadership skills. We aim to make use of each individual´s specific interests and expertise. Depending on the expertise of the chosen candidate, she/he may either concentrate on a novel project for development of CAR T cell therapy overcoming immune suppression in solid tumours or on a translational project for identification of biomarkers for clinical response to checkpoint inhibitors, based on material from the above mentioned clinical trials. The candidate will be encouraged to take initiatives for developing the projects and will be expected to provide supervision within her/his area of expertise.
Strong research background in immunology, molecular biology or biostatistics, including a degree equivalent to a Norwegian PhD and at least one postdoc period.
A proven record of research, evidenced by successful publishing in scientific journals
Experience in immunology and molecular biology will be important assets, in particular experience in CAR/TCR studies, animal models, flow cytometry/CyTOF, multimer and T-cell functional assays, and knowledge on mechanisms for immune suppression
Knowledge in complex statistical analyses of large data sets will be an asset
Excellent written and oral communication skills (English)
Strong motivation and excellent ability to collaborate
Excellent ability to work independently
Experience and personal qualifications that will enable the candidate to take a senior responsibility as deputy group leader
Ability to take initiatives, interact with collaborators and contribute to the strategic decisions advancing the projects
College / University, Doctorate
The possibility to combine active research with the development of leadership skills
Interesting and challenging research projects in a hot-topic area, with huge potential for clinical application
A possibility to gain experience in new technologies
A productive and motivating research environment
Full-time three-year position
Salary for researcher or senior scientist, according to the OUS salary scale
Favorable pension arrangements
Attractive welfare arrangements
Jon Amund Kyte
(47) 22 93 50 46 / (47) 22 78 13 13